SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that in partnership with its collaborators it will present key clinical updates on its investigational products JCAR014, JCAR015 and JCAR017 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2016 in Chicago, Illinois from June 3-7.
